Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 323

1.

Practical management of patients on Janus kinase inhibitor (JAKi) therapy: Practical fact sheets drawn up by the Rheumatism and Inflammation Club (CRI), a group endorsed by the French Society for Rheumatology (SFR).

Richez C, Morel J, Cornec D, Daïen C, Goupille P, Lazaro E, Lequerré T, Nocturne G, de Lédinghen V, Le Goff B, Pourcher V, Prati C, Seror R, Tournadre A, Truchetet ME, Sibilia J, Pham T.

Joint Bone Spine. 2019 Oct;86 Suppl 1:eS2-eS103. doi: 10.1016/S1297-319X(19)30154-X. Epub 2019 Oct 31. No abstract available.

PMID:
31791545
2.

Practical management of patients on Janus kinase inhibitor (JAKi) therapy - the CRI fact sheets.

Richez C, Morel J, Sibilia J, Pham T; In the name of the CRI and the team of expert authors.

Joint Bone Spine. 2019 Oct;86 Suppl 1:eS1. doi: 10.1016/S1297-319X(19)30153-8. Epub 2019 Oct 31. No abstract available.

PMID:
31791544
3.

Incidence and risk factors for gangrene in patients with systemic sclerosis from the EUSTAR cohort.

Mihai C, Distler O, Gheorghiu AM, Constantin PI, Dobrota R, Jordan S, Smith V, Hachulla E, Henes J, Siegert E, Vettori S, Müller-Ladner U, Matucci Cerinic M, Allanore Y; EUSTAR .

Rheumatology (Oxford). 2019 Dec 2. pii: kez558. doi: 10.1093/rheumatology/kez558. [Epub ahead of print]

PMID:
31790136
4.

Racial differences in systemic sclerosis disease presentation: a European Scleroderma Trials and Research group study.

Jaeger VK, Tikly M, Xu D, Siegert E, Hachulla E, Airò P, Valentini G, Matucci Cerinic M, Distler O, Cozzi F, Carreira P, Allanore Y, Müller-Ladner U, Ananieva LP, Balbir-Gurman A, Distler JHW, Czirják L, Li M, Henes J, Jimenez SA, Smith V, Damjanov N, Denton CP, DelGaldo F, Saketkoo LA, Walker UA; EUSTAR co-authors .

Rheumatology (Oxford). 2019 Nov 4. pii: kez486. doi: 10.1093/rheumatology/kez486. [Epub ahead of print]

PMID:
31680161
5.

Comparative effect of tumour necrosis factor inhibitors versus other biological agents on cardiovascular risk-associated biomarkers in patients with rheumatoid arthritis.

Virone A, Bastard JP, Fellahi S, Capeau J, Rouanet S, Sibilia J, Ravaud P, Berenbaum F, Gottenberg JE, Sellam J.

RMD Open. 2019 Jul 21;5(2):e000897. doi: 10.1136/rmdopen-2019-000897. eCollection 2019.

6.

T1 mapping cardiac magnetic resonance imaging frequently detects subclinical diffuse myocardial fibrosis in systemic sclerosis patients.

Poindron V, Chatelus E, Canuet M, Gottenberg JE, Arnaud L, Gangi A, Gavand PE, Guffroy A, Korganow AS, Germain P, Sibilia J, El Ghannudi S, Martin T.

Semin Arthritis Rheum. 2019 Jun 19. pii: S0049-0172(18)30711-X. doi: 10.1016/j.semarthrit.2019.06.013. [Epub ahead of print]

7.

Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis.

Becker M, Graf N, Sauter R, Allanore Y, Curram J, Denton CP, Khanna D, Matucci-Cerinic M, de Oliveira Pena J, Pope JE, Distler O; EUSTAR Collaborators; EUSTAR Collaborators (numerical order of centres).

Ann Rheum Dis. 2019 Sep;78(9):1242-1248. doi: 10.1136/annrheumdis-2019-215145. Epub 2019 Jun 21.

8.

Anti-Ku syndrome with elevated CK and anti-Ku syndrome with anti-dsDNA are two distinct entities with different outcomes.

Spielmann L, Nespola B, Séverac F, Andres E, Kessler R, Guffroy A, Poindron V, Martin T, Geny B, Sibilia J, Meyer A.

Ann Rheum Dis. 2019 Aug;78(8):1101-1106. doi: 10.1136/annrheumdis-2018-214439. Epub 2019 May 24.

PMID:
31126956
9.

Long-term safety and effectiveness of tocilizumab in patients with rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: an open-label study close to clinical practice.

Bykerk VP, Östör AJK, Alvaro-Gracia J, Pavelka K, Román Ivorra JA, Nurmohamed MT, Luder Y, Sidiropoulos PNM, Devenport J, Sibilia J.

Clin Rheumatol. 2019 Sep;38(9):2411-2421. doi: 10.1007/s10067-019-04535-z. Epub 2019 Apr 26.

PMID:
31028551
10.

The world-wide burden of musculoskeletal diseases: a systematic analysis of the World Health Organization Burden of Diseases Database.

Sebbag E, Felten R, Sagez F, Sibilia J, Devilliers H, Arnaud L.

Ann Rheum Dis. 2019 Jun;78(6):844-848. doi: 10.1136/annrheumdis-2019-215142. Epub 2019 Apr 15.

PMID:
30987966
11.

[Periodic certification of physicians for personalized professional development].

Sibilia J.

Rev Prat. 2019 Feb;69(2):135-136. Review. French. No abstract available.

PMID:
30983209
12.

Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis.

Sobanski V, Giovannelli J, Allanore Y, Riemekasten G, Airò P, Vettori S, Cozzi F, Distler O, Matucci-Cerinic M, Denton C, Launay D, Hachulla E; EUSTAR Collaborators.

Arthritis Rheumatol. 2019 Sep;71(9):1553-1570. doi: 10.1002/art.40906. Epub 2019 Aug 12.

13.

Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study.

Elhai M, Boubaya M, Distler O, Smith V, Matucci-Cerinic M, Alegre Sancho JJ, Truchetet ME, Braun-Moscovici Y, Iannone F, Novikov PI, Lescoat A, Siegert E, Castellví I, Airó P, Vettori S, De Langhe E, Hachulla E, Erler A, Ananieva L, Krusche M, López-Longo FJ, Distler JHW, Hunzelmann N, Hoffmann-Vold AM, Riccieri V, Hsu VM, Pozzi MR, Ancuta C, Rosato E, Mihai C, Kuwana M, Saketkoo LA, Chizzolini C, Hesselstrand R, Ullman S, Yavuz S, Rednic S, Caimmi C, Bloch-Queyrat C, Allanore Y; for EUSTAR network.

Ann Rheum Dis. 2019 Jul;78(7):979-987. doi: 10.1136/annrheumdis-2018-214816. Epub 2019 Apr 9.

PMID:
30967395
14.

The pipeline of targeted therapies under clinical development for primary Sjögren's syndrome: A systematic review of trials.

Felten R, Scher F, Sibilia J, Gottenberg JE, Arnaud L.

Autoimmun Rev. 2019 Jun;18(6):576-582. doi: 10.1016/j.autrev.2018.12.008. Epub 2019 Apr 6.

PMID:
30959220
15.

The IgG2 Isotype of Anti-Transcription Intermediary Factor 1γ Autoantibodies Is a Biomarker of Cancer and Mortality in Adult Dermatomyositis.

Aussy A, Fréret M, Gallay L, Bessis D, Vincent T, Jullien D, Drouot L, Jouen F, Joly P, Marie I, Meyer A, Sibilia J, Bader-Meunier B, Hachulla E, Hamidou M, Huë S, Charuel JL, Fabien N, Viailly PJ, Allenbach Y, Benveniste O, Cordel N, Boyer O; OncoMyositis Study Group.

Arthritis Rheumatol. 2019 Aug;71(8):1360-1370. doi: 10.1002/art.40895. Epub 2019 Jul 8.

PMID:
30896088
16.

Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort.

Wu W, Jordan S, Graf N, de Oliveira Pena J, Curram J, Allanore Y, Matucci-Cerinic M, Pope JE, Denton CP, Khanna D, Distler O; EUSTAR Collaborators.

Ann Rheum Dis. 2019 May;78(5):648-656. doi: 10.1136/annrheumdis-2018-213455. Epub 2019 Mar 9.

17.

Muscle fluorodeoxyglucose uptake assessed by positron emission tomography-computed tomography as a biomarker of inflammatory myopathies disease activity.

Matuszak J, Blondet C, Hubelé F, Gottenberg JE, Sibilia J, Bund C, Geny B, Namer IJ, Meyer A.

Rheumatology (Oxford). 2019 Mar 8. pii: kez040. doi: 10.1093/rheumatology/kez040. [Epub ahead of print]

PMID:
30851092
18.

Revisiting the Association Between Systemic Lupus Erythematosus and Gout.

Aguiar F, Brito I, Sibilia J.

Reumatol Clin. 2019 Mar 2. pii: S1699-258X(19)30029-4. doi: 10.1016/j.reuma.2019.01.001. [Epub ahead of print] English, Spanish. No abstract available.

19.

Drug-induced systemic lupus: revisiting the ever-changing spectrum of the disease using the WHO pharmacovigilance database.

Arnaud L, Mertz P, Gavand PE, Martin T, Chasset F, Tebacher-Alt M, Lambert A, Muller C, Sibilia J, Lebrun-Vignes B, Salem JE.

Ann Rheum Dis. 2019 Apr;78(4):504-508. doi: 10.1136/annrheumdis-2018-214598. Epub 2019 Feb 4.

PMID:
30793701
20.

Strategy for suspected myositis.

Meyer A, Sibilia J.

Joint Bone Spine. 2019 Oct;86(5):568-575. doi: 10.1016/j.jbspin.2019.01.013. Epub 2019 Feb 1.

PMID:
30711692

Supplemental Content

Loading ...
Support Center